Business context and reporting period
Source and period mismatch: The supplied filing is Adtalem Global Education Inc.’s Form 10-K for the fiscal year ended June 30, 2022, filed August 11, 2022—not a Covista Inc. filing or a 2021 Q4 filing. The summary below therefore covers Adtalem’s FY2022; Q4 figures are noted separately where provided.
Adtalem is a healthcare-focused education company with Chamberlain University, Walden University, and Medical and Veterinary (AUC, RUSM, and RUSVM) segments. It acquired Walden for approximately $1.5 billion in August 2021 and sold ACAMS, Becker, and OnCourse Learning in March 2022, followed by EduPristine in June. Those divested businesses are reported as discontinued operations.
Financial and operating metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $1,387.1 million | $906.9 million |
| Operating income | $80.5 million; 5.8% margin | $118.1 million; 13.0% margin |
| Continuing operations income (loss) | $(29.8) million | $70.3 million |
| Net income attributable to Adtalem | $317.7 million; diluted EPS $6.57 | $76.9 million; diluted EPS $1.49 |
| Continuing-operations income excluding special items (non-GAAP) | $158.2 million; diluted EPS $3.24 | $119.2 million; diluted EPS $2.31 |
| Operating cash flow from continuing operations | $163.8 million | $168.8 million |
| Capital expenditures | $31.1 million | $39.9 million |
| Cash and cash equivalents at year-end | $347.0 million | $476.4 million |
| Debt principal outstanding at year-end | $859.2 million | $1,091.0 million |
FY2022 net income included a $473.5 million pretax gain on disposal of discontinued businesses, partly offset by $125.6 million of related tax expense. Continuing operations recorded a loss despite positive operating income, largely reflecting $129.3 million of interest expense. The filing reports gross margin as cost of educational services divided by revenue: educational-service costs were 47.6% of revenue, versus 50.5% in FY2021. Student services and administrative expense rose to 41.0% of revenue from 32.3%.
Revenue increased 53.0% as reported, primarily due to Walden; excluding the acquisition, revenue declined 0.6%. Segment revenue was $557.5 million at Chamberlain (down 1.1%), $485.4 million at Walden (owned only since August 2021), and $344.2 million at Medical and Veterinary (up 0.3%).
FY2022 Q4, if that was the intended comparison: Revenue was $361.2 million, operating income $44.5 million, continuing-operations income $2.5 million, discontinued-operations income $5.6 million, and net income $8.0 million; diluted EPS was $0.18.
At June 30, 2022, the $400 million revolving facility had $316 million available after an $84 million letter of credit. On July 14, 2022, that letter was replaced with a surety-backed letter, bringing stated revolver availability to $400 million as of the filing date. The company reported compliance with its debt covenants. The Term Loan B rate was 5.60%; management estimated a 100-basis-point increase in short-term rates would add about $4.5 million in annual interest expense.
Material changes, outlook, and risks
- Acquisition and portfolio shift: Walden contributed $485.4 million revenue and a $3.1 million net loss after acquisition. FY2022 included $53.2 million of acquisition and integration costs, $25.6 million of restructuring expense, and $97.3 million of Walden intangible amortization. Management expected further integration and restructuring costs in FY2023.
- Enrollment: May 2022 Chamberlain enrollment declined 5.8% year over year; Walden enrollment at June 30 declined 9.5% on the comparative figures cited in the filing. Medical and Veterinary enrollment increased 3.5% for the May 2022 semester. Management cited healthcare-sector disruption, competition, and other factors; it said COVID-related revenue effects at Chamberlain and Walden were not quantifiable.
- Cash deployment and shareholder returns: The company paid $150 million under an accelerated share repurchase and made substantial debt prepayments, including a $396.7 million Term Loan B prepayment and repayment/repurchase of Notes. It authorized a further $300 million share-repurchase program through February 2025; no purchases were made under that program in FY2022. No cash dividends were paid, and none were expected in the foreseeable future.
- Management outlook: Management believed cash, operating cash generation, and the credit facility would fund operations and growth plans for the foreseeable future. FY2023 capital spending was projected at $60–$70 million. Management expected COVID-related uncertainty to continue affecting enrollment and potentially results, and expected to transition LIBOR-based debt terms to SOFR during FY2023.
- Regulatory and legal exposure: Title IV funding represented 72% of revenue in FY2021; FY2022 data was not yet available. Management expected the consolidated federal financial-responsibility composite score to fall below the 1.5 benchmark for FY2022, potentially bringing additional oversight, cash monitoring, or collateral requirements. Walden remained on a temporary provisional participation agreement, with an $84 million letter of credit in place at year-end. The filing also describes pending litigation and regulatory matters, including DeVry-related claims and a Walden doctoral-program class action; outcomes and potential financial effects were uncertain.
- Other notable risks: Higher debt and interest costs following the acquisition; failure to realize anticipated synergies; competition and declining enrollment; dependence on federal student aid; accreditation and state authorization requirements; possible impairment of goodwill and intangible assets; and cybersecurity, privacy, and pandemic-related risks. Goodwill was $961.3 million and intangible assets were $873.6 million at year-end. No impairment was recorded in FY2022. The independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Investor facts to verify
- Confirm the intended issuer and period: the supplied document is Adtalem FY2022, not Covista or FY2021 Q4.
- Review continuing-operations performance separately from the $473.5 million disposal gain; reported FY2022 net income substantially reflects discontinued operations.
- Assess the durability of enrollment and revenue after Walden’s acquisition, particularly at Chamberlain and Walden.
- Check progress on Walden’s provisional Title IV status and the consolidated financial-responsibility score, including any resulting cash-monitoring or collateral requirements.
- Verify actual debt reduction, interest expense, revolver availability, and FY2023 capital spending against management’s expectations.
- Track integration costs and synergy delivery, pending litigation, and impairment sensitivity for the substantial goodwill and intangible-asset balances.